December 10, 2024
Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions
December 9, 2024
Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone
November 14, 2024
Akoya Biosciences Reports Third Quarter 2024 Financial Results
November 5, 2024
Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel
October 28, 2024
Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024
October 7, 2024
Akoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy
October 3, 2024
Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors
August 5, 2024
Akoya Biosciences Reports Second Quarter 2024 Financial Results
July 15, 2024
Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences
May 13, 2024
Akoya Biosciences Reports First Quarter 2024 Financial Results
Displaying 1 - 10 of 22